Search | Clinical Trials Finder

Conditions: Bronchiolitis Obliterans Syndrome
Interventions: Pulmonary function testing, FAM Therapy; Procedure · Drug
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 6 Years to 18 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Asthma
Interventions: FF/GSK573719, FF, FF/VI; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 4
States / cities: St Louis, Missouri • Medford, Oregon • Orangeburg, South Carolina + 1 more

Conditions: Nasal Polyps
Interventions: Fluticasone Propionate; Drug
Lead sponsor: Optinose US Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 16
States / cities: Birmingham, Alabama • Brandon, Florida • Normal, Illinois + 13 more

Conditions: Polyp of Nasal Sinus
Interventions: Doxycycline, methylprednisolone, nasal saline spray, Flonase, sugar pill; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Persistent Asthma
Interventions: QAW039 capsules once daily for 28 days, Placebo to QAW039 capsules once daily for 28 days, Fluticasone propionate inhaler twice daily for 28 days; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 18
States / cities: Encinitas, California • Huntington Beach, California • Los Angeles, California + 13 more

Conditions: Asthma
Interventions: Placebo, UMEC, Fluticasone Furoate, Albuterol/salbutamol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 19
States / cities: Tempe, Arizona • Rolling Hills Estates, California • Colorado Springs, Colorado + 15 more

Conditions: Suspected Eosinophilic Esophagitis
Interventions: Esophageal dilation, Steroid and Proton Pump Inhibitor Therapy; Procedure · Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Asthma
Interventions: SAR440340, Dupilumab, Fluticasone or Fluticasone/salmeterol combination, Placebo for SAR440340, Placebo for dupilumab; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 18
States / cities: Birmingham, Alabama • Long Beach, California • Los Angeles, California + 14 more

Conditions: Seasonal Allergic Rhinitis
Interventions: Azelastine hydrochloride and Fluticasone propionate, Dymista™, Placebo; Drug · Other
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 12 Years and older
Enrollment: 1,535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: COPD
Interventions: Fluticasone Furoate-Vilanterol Trifenatate, Furoate-umeclidinium-vilanterol; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 40 Years to 120 Years
Enrollment: 17,281 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Asthma
Interventions: GW685698X, placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 622 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 95
States / cities: Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 82 more

Conditions: Seasonal Allergic Rhinitis
Interventions: Placebo, azelastine Hcl, azelastineHcl / fluticasone propionate, fluticasone propionate; Drug
Lead sponsor: Meda Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 832 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 43
States / cities: Scottsdale, Arizona • Encinitas, California • Los Angeles, California + 38 more

Conditions: Seasonal Allergic Rhinitis
Interventions: Olopatadine HCL Nasal Spray, 0.6%, Fluticasone Propionate Nasal Spray, 50 mcg; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 12 Years and older
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: FF, UMEC, VI; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 338 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 14
States / cities: Newport Beach, California • San Diego, California • Upland, California + 11 more

Conditions: Eosinophilic Esophagitis
Interventions: Cortisol level; Diagnostic Test
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 85 Years
Enrollment: 300 participants
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Asthma
Interventions: TEV-56248, Fp MDPI; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 10
States / cities: Mobile, Alabama • Long Beach, California • Miami, Florida + 5 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Tiotropium, Olodaterol, Fluticasone propionate, Salmeterol; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 45
States / cities: Jasper, Alabama • Flagstaff, Arizona • Fullerton, California + 40 more

Conditions: Asthma, Candidiasis, Oral, Voice Disorders
Interventions: fluticasone/salmeterol DISKUS 250/50; Drug
Lead sponsor: Allergy & Asthma Medical Group & Research Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: San Diego, California

Conditions: Rhinitis, Allergic, Perennial and Seasonal
Interventions: FPNS, FPNS Placebo, Cetirizine, Cetirizine Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 682 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 31
States / cities: Little Rock, Arkansas • Denver, Colorado • Aventura, Florida + 27 more

Conditions: Asthma
Interventions: clarithromycin, fluticasone propionate, placebo clarithromycin; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 10
States / cities: San Diego, California • San Francisco, California • Denver, Colorado + 7 more

Conditions: Pulmonary Disease, Chronic Obstructive, Pneumonia, Bacterial
Interventions: Bronchoscopy with bilateral bronchoalveolar lavages; Procedure
Lead sponsor: VA Ann Arbor Healthcare System; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Asthma
Interventions: BI 671800, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 14
States / cities: Huntington Beach, California • Mission Viejo, California • Stockton, California + 11 more

Conditions: Asthma
Interventions: Fluticasone furoate/ Vilanterol 100 mcg/25 mcg, Fluticasone propionate 250 mcg, Placebo via ELLIPTA inhaler, Placebo via DISKUS / ACCUHALER; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years to 50 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 13
States / cities: Huntington Beach, California • Los Angeles, California • San Diego, California + 9 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Batefenterol + Fluticasone Furoate, Placebo, Albuterol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 10
States / cities: Phoenix, Arizona • Hollywood, Florida • Baltimore, Maryland + 7 more

Search by objective public record fields.

Early Detection and Management of Bronchiolitis Obliterans Syndrome Following Pediatric Hematopoietic Stem Cell Transplantation

Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination With Fluticasone Furoate in Subjects With Asthma

12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose Device

Doxycycline in Treating Patients With Chronic Rhinosinusitis With Nasal Polyps

Efficacy, Safety, and Pharmacokinetics of QAW039

Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma

Study of the Efficiency of Esophageal Dilation on Patient With Eosinophilic Esophagitis

Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants

Clinical Equivalence of Azelastine Hydrochloride and Fluticasone Propionate, 137/50 mcg Nasal Spray to Dymista™

Replication of the IMPACT COPD Trial in Healthcare Claims Data

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Low-Dose ICS Therapy.

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

Comparison of Olopatadine 0.6% and Fluticasone Proprionate 50mcg Nasal Sprays in a Two Week Seasonal Allergic Rhinitis Trial

Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component

Evaluating Adrenal Insufficiency in Adults With Eosinophilic Esophagitis on Chronic Swallowed Topical Steroids

Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old

The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus

Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 mcg BID

A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis

Asthma Clinical Research Network (ACRN) Trial - Macrolides in Asthma (MIA)

Modulation of Steroid Immunosuppression by Alveolar Efferocytosis

Bi 671800 in Asthmatic Patients on Inhaled Corticosteroids

Crossover Study Comparing Fluticasone Furoate (FF)/Vilanterol (VI) Once Daily Versus Fluticasone Propionate (FP) Twice Daily in Subjects With Asthma and Exercise-Induced Bronchoconstriction (EIB)

Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease